Effect and Mechanism of Midostaurin Derivatives 5'''-methoxyfradcarbazole A on Mouse Leukemia CB3 Cells
RAO Qing1, WANG Li-ping1, ZHU Wei-ming1,2, CHEN Juan1, SONG Jing-rui1, LI Yan-mei1*
1. The State Key Laboratory of Functions and Applications of Medicinal Plants, The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academy of Sciences, Guiyang 550014, China; 2. Ocean University of China, Qingdao 266100, China
Abstract：OBJECTIVE To investigate the mechanism of midostaurin derivative 5'''-methoxyfradcarbazole A of action in inhibiting mouse leukemia cells (CB3) growth. METHODS MTT assay was employed to evaluate the effect of compound 5'''-methoxyfradcarbazole A on the proliferation of CB3 cells, and generate the growth inhibition curves. Flow cytometry and Annexin V-FITC /PI double staining were used to determine the changes of the cell cycle, cell differentiation and apoptosis. Western blot analysis was applied to test the effects of 5'''-methoxyfradcarbazole A on cyclin and apoptosis-related proteins. RESULTS The compound 5'''-methoxyfradcarbazole A could significantly inhibit the growth of CB3 cells, and the half maximal inhibitory concentration (IC50) of the compound was (0.587±0.135)μmol·L-1. 5'''-Methoxyfradcarbazole A was able to induce early apoptosis and late apoptosis of CB3 cells in a time- and dose-dependent manner. At the same time, it also affected the cell cycle of CB3 and significantly increased the proportion of G2 phase. The expression of CD41, a platelet differentiation marker, and Ter119, an erythrocyte differentiation marker, were also increased in CB3 cells treated with 5'''-methoxyfradcarbazole A. Besides, the expressions of apoptosis-related proteins Bim, PARP1 and cyclin-related protein P21 were significantly increased, and the phosphorylated ERK protein was decreased. CONCLUSION Midostaurin derivative 5'''-methoxyfradcarbazole A could increase the apoptosis of CB3 cells by promoting the expression of apoptotic protein Bim, and cause G2 phase arrest by increasing the expression of cyclin protein P21. Also, the changes of the expression levels of PARP1 and phosphorylated ERK protein also partly explain the inhibition of 5'''-methoxyfradcarbazole A on CB3 cells growth.
FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015,136(5):359-386.
[2]
WELCH J S, LEY T J, LINK D C, et al. The origin and evolution of mutations in acute myeloid leukemia [J]. Cell, 2012, 150(2):264-278.
[3]
GALLOGLY M M, LAZARUS H M, COOPER B W. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis [J]. Ther Adv Hematol, 2017, 8(9):245-261.
[4]
FABBRO D B E, WOOD J, MESTAN J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent [J]. Pharmacol Ther, 1999, 82(2-3):293-301.
[5]
COOLS J, MENTENS N, FURET P, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia [J]. Cancer Res, 2004, 64(18):6385-6389.
[6]
HEIDEL F, SOLEM F K, BREITENBUECHER F, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain [J]. Blood, 2006, 107(1):293-300.
[7]
WILLIAMS A B, NGUYEN B, LI L, et al. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors [J]. Leukemia, 2013, 27(1):48-55.
[8]
CARAVATTI G M T, FREDENHAGEN A, TRINKS U, et al. Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C [J]. Bioorg Med Chem Lett, 1994, 4(3):399-404.
[9]
MEYER T R U, FABBRO D, ALTERI E, et al. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity [J]. Int J Cancer, 1989, 43(5):851-856.
[10]
IKEGAMI Y, YANO S, NAKAO K. Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells [J]. Jpn J Pharmacol, 1996, 70(1):65-72.
[11]
IKEGAMI Y, YANO S, NAKAO K. Effects of the new selective protein kinase C inhibitor 49-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells [J]. Arzneimittelforschung, 1996, 46(2):201-204.
[12]
HANAHAN D, WEINBERG R A. The hallmarks of cancer [J]. Cell, 2000, 100(1):57-70.
[13]
FISHER D E. Apoptosis in cancer therapy: crossing the threshold [J]. Cell, 1994, 78(4):539-542.
[14]
BROWN J M, ATTARDI L D. The role of apoptosis in cancer development and treatment response [J]. Nat Rev Cancer, 2005, 5(3):231-237.
[15]
KAPOOR R, RIZVI F, KAKKAR P. Naringenin prevents high glucose-induced mitochondria-mediated apoptosis involving AIF, Endo-G and caspases [J]. Apoptosis, 2013,18(1):9-27.
[16]
ELMORE S. Apoptosis: a review of programmed cell death [J]. Toxicol Pathol, 2007, 35(4):495-516.
[17]
CORY S, ADAMS J M. The Bcl2 family: regulators of the cellular life-or-death switch [J]. Nat Rev Cancer, 2002, 2(9):647-656.
[18]
ELMORE S. Apoptosis: a review of programmed cell death [J]. Toxicol Pathol, 2007, 35(4):495-516.
[19]
BOUILLET P. Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity [J]. Science, 1999, 286(5445):1735-1738.
[20]
SHUKLA S, SAXENA S, SINGH B K, et al. BH3-only protein BIM: an emerging target in chemotherapy [J]. Eur J Cell Biol, 2017, 96(8):728-738.
[21]
ZHAO L, LI J, SU J, et al. LS8 cell apoptosis induced by NaF through p-ERK and p-JNK-a mechanism study of dental fluorosis [J]. Acta Odontol Scand, 2016, 74(7):539-549.
[22]
JAGTAP P, SZABO C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors [J]. Nat Rev Drug Discov, 2005, 4(5):421-440.
[23]
BOUCHER M J, MORISSET J, VACHON P H, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells [J]. J Cell Biochem, 2000, 79(3):355-369.
[24]
FRIZZELL K M, GAMBLE M J, BERROCAL J G, et al. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells [J]. J Biol Chem, 2009, 284(49):33926-33938.
[25]
MALUMBRES M, BARBACID M. Mammalian cyclin-dependent kinases [J]. Trends Biochem Sci, 2005, 30(11):630-641.
[26]
ABBAS T, DUTTA A. p21 in cancer: intricate networks and multiple activities [J]. Nat Rev Cancer, 2009, 9(6):400-414.
[27]
BATES S, RYAN K M, PHILLIPS A C, et al. Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression [J]. Oncogene, 1998, 17(13):1691-1703.
[28]
MEDEMA R H, KLOMPMAKER R, SMITS V A, et al. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases [J]. Oncogene, 1998, 16(4):431-441.
[29]
DULIC′ V, STEIN G H, FAR D F, et al. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition [J]. Mol Cell Biol, 1998, 18(1):546-557.
2020, Vol. 55 
